Text message neck syndrome represents a significant epidemiological and musculoskeletal concern arising from repetitive strain and prolonged cervical flexion during mobile device operation. Anatomical deviations associated with this syndrome, such as anterior head translation and altered lower cervical alignment, substantially increase the gravitational load exerted on the cervical spine. This progressive mechanical overload predisposes individuals to microtraumas, paraspinal muscle imbalances, and secondary proprioceptive impairments. Kinematic variations further heighten the clinical vulnerability of female populations, as distinct sagittal and thoracic parameters accelerate the progression of postural dysfunction.Conventional therapeutic strategies frequently target localized cervical symptoms, often neglecting the broader kinetic chain and the interdependent relationship between the cervical and thoracic segments. To address these limitations, this clinical trial evaluates a holistic "joint-by-joint" rehabilitation framework by incorporating thoracic spine interventions into both active protocols. The Mulligan Mobilization Technique combines passive manual facet joint glides with active physiological movements to restore biomechanical alignment and reduce nociceptive mechanical stress. Conversely, the Spinal Stabilization Training Protocol focuses on neuromuscular control, utilizing a pressure biofeedback unit and progressive resistance to enhance the endurance of deep cervical flexors and stabilize the scapulothoracic region.A major gap in text neck syndrome literature is the reliance on subjective pain scales, leaving the underlying neurobiological mechanisms under-investigated. This study introduces an objective biochemically validated assessment model by quantifying objective biomarkers of neurogenic inflammation, nociception, and central sensitization. By analyzing pre- and post-intervention serum concentrations of Calcitonin Gene-Related Peptide (CGRP) and Substance P via enzyme-linked immunosorbent assay (ELISA), this trial aims to correlate clinical sensorimotor and postural improvements with neurochemical changes. Ultimately, the findings will clarify whether passive manual joint mobilization or progressive active stabilization exercise provides superior efficacy in restoring sensorimotor function, optimizing postural stability, and mitigating chronic neurogenic pain pathways.
Age range
18 Years – 30 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Visual Analogue Scale (VAS)
Timeframe: Baseline and Post-treatment (4 weeks)
Neck Disability Index (NDI)
Timeframe: Baseline and Post-treatment (4 weeks)
Cervical Range of Motion (CROM)
Timeframe: Baseline and Post-treatment (4 weeks)
Cervical Joint Position Sense (JPS)
Timeframe: Baseline and Post-treatment (4 weeks)
Postural Stability (Sway Medical Application)
Timeframe: Baseline and Post-treatment (4 weeks)
Dynamic Balance (Y-Balance Test)
Timeframe: Baseline and Post-treatment (4 weeks)
Cervical Deep Flexor Muscle Endurance
Timeframe: Baseline and Post-treatment (4 weeks)
Gaze Stability (Head-Eye Movement Control Test)
Timeframe: Baseline and Post-treatment (4 weeks)
Sagittal Posture Angles (CVA and CTA)
Timeframe: Baseline and Post-treatment (4 weeks)
Biochemical Marker: Calcitonin Gene-Related Peptide (CGRP)
Timeframe: Baseline and Post-treatment (4 weeks)
Biochemical Marker: Substance P (SP)
Timeframe: Baseline and Post-treatment (4 weeks)